Related Experiment Video
Updated: Aug 12, 2025

Bio-layer Interferometry for Measuring Kinetics of Protein-protein Interactions and Allosteric Ligand Effects
Published on: February 18, 2014
Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2
Carrie S Tambo1, Sarvind Tripathi1, B Gayani K Perera2
1Department of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, United States.
Abstract:
Cyclin-dependent kinases (CDKs) are key mediators of cell proliferation and have been a subject of oncology drug discovery efforts for over two decades. Several CDK and activator cyclin family members have been implicated in regulating the cell division cycle. While it is thought that there are canonical CDK-cyclin pairing preferences, the extent of selectivity is unclear, and increasing evidence suggests that the cell-cycle CDKs can be activated by a pool of available cyclins. The molecular details of CDK-cyclin specificity are not completely understood despite their importance for understanding cancer cell cycles and for pharmacological inhibition of cancer proliferation. We report here a biolayer interferometry assay that allows for facile quantification of CDK binding interactions with their cyclin activators. We applied this assay to measure the impact of Cdk2 inhibitors on Cyclin A (CycA) association and dissociation kinetics. We found that Type I inhibitors increase the affinity between Cdk2 and CycA by virtue of a slowed cyclin dissociation rate. In contrast, Type II inhibitors and other small-molecule Cdk2 binders have distinct effects on the CycA association and dissociation processes to decrease affinity. We propose that the differential impact of small molecules on the cyclin binding kinetics arises from the plasticity of the Cdk2 active site as the kinase transitions between active, intermediate, and inactive states.
Insights
New research reveals how Cdk2 inhibitors affect cyclin binding. Type I inhibitors strengthen Cdk2-Cyclin A bonds by slowing dissociation, while Type II inhibitors weaken them, impacting cancer drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cyclin-dependent kinases (CDKs) are crucial for cell proliferation and are targets in cancer drug discovery.
- Understanding CDK-cyclin interactions is vital for cancer therapy, but specificity remains unclear.
- CDK-cyclin binding kinetics influence cell cycle regulation and drug efficacy.
Purpose of the Study:
- To develop a biolayer interferometry assay for quantifying CDK-cyclin binding.
- To investigate the impact of Cdk2 inhibitors on Cyclin A (CycA) binding kinetics.
- To elucidate the molecular mechanisms behind CDK-cyclin specificity and drug interactions.
Main Methods:
- Developed a biolayer interferometry assay to measure CDK-cyclin binding kinetics.
- Quantified association and dissociation rates of Cdk2 with Cyclin A (CycA).
- Assessed the effects of Type I and Type II Cdk2 inhibitors on CycA binding.
Main Results:
- Type I Cdk2 inhibitors increased Cdk2-CycA affinity by slowing cyclin dissociation.
- Type II inhibitors and other small molecules decreased affinity through altered association/dissociation kinetics.
- Differential effects of inhibitors suggest Cdk2 active site plasticity influences cyclin binding.
Conclusions:
- The developed assay facilitates CDK-cyclin interaction analysis.
- Cdk2 inhibitor mechanisms vary, impacting cyclin binding kinetics differently.
- CDK active site dynamics are key to understanding drug interactions and developing targeted cancer therapies.
More Related Videos
12:26Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Inhibition of Cdk Activity
Positive Regulator Molecules